Skip to content
mielomamultiplo.com · Multiple Myeloma
Emergency 112  · SNS 24 808 24 24 24
The Multiple Myeloma symbol — find out what it means

Multiple Myeloma There is hope. There is a way forward.

information · support · hope

It is always better to be an informed patient.

News, testimonies, a space to share ideas and links that help patients and carers understand the disease better and know where to find help.

Automatic translation by MielomaAI. The original text is in Portuguese. Some parts may still appear in Portuguese while they are being translated. Português
Summary · Treatments

Multiple myeloma therapies are evolving rapidly. Recently, in Portugal, the inhibition of the NFIL3-MYC axis has shown to overcome treatment resistance in high-risk patients. New approaches, such as CAR-T therapies and antibody combinations, are being explored in various countries, including Canada and the USA, with the aim of improving access to treatments.

Made by MielomaAI On November 17, 2026, at 11:05, based on recent news. May contain errors. View news →

In the last 3 months. On the site you’ll find the news from the last 3 months. The older ones only have the title and a link, in file by topicsIt’s a support website for people with multiple myeloma. It aims to keep things simple and clear. MielomaAI As you may find.

News · 37

Collected from Portuguese newspapers, Google News (PT, EN, ES, FR) and associations and scientific societies. They are on the website 197 news: only from the last 3 months. The older ones are only shown with the title and link, in file by topicsAnd research and the MielomaAI You continue to find them. Always consult the original news article and speak with your doctor before drawing conclusions about your case. Last update: November 17, 2026, 3:21 PM.

Monday, 16/11

Sunday, November 15

Friday, November 13

Thursday, November 12th

  • Referral Before Salvage Therapy Keeps CAR T an Option in Myeloma
    Targeted Onc (EUA) · 22:08 TratamentosEUA

    During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.

  • How Etentamig Stands Out From Other BCMA Bispecifics
    Targeted Onc (EUA) · 22:00 TratamentosEUA

    Peter Voorhees, MD, explains how etentamig differentiates itself from other BCMA bispecifics for multiple myeloma through a strategic engineering choice: a low-affinity CD3 binding domain. By intentionally reducing this affinity, the design aims to mitigate severe cytokine release syndrome. It can also be given on an…

  • CELMoDs as Holding and Bridging Therapy in Multiple Myeloma
    CancerNetwork (EUA) · 15:43 TratamentosEUA

    In this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith explore the potential role of cereblon E3 ligase modulators (CELMoDs) as holding and bridging therapies for patients with multiple myeloma preparing for chimeric antigen receptor (CAR) T-cell therapy.

  • CELMoDs With CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
    CancerNetwork (EUA) · 13:13 TratamentosEUA

    In this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss the potential role of cereblon E3 ligase modulators (CELMoDs) following chimeric antigen receptor (CAR) T-cell therapy and in combination with bispecific antibodies for multiple myeloma.

Wednesday, 11/11

Tuesday, November 10

Monday, November 9th

Friday, November 6th

Wednesday, 11/04

Tuesday, November 3rd

Monday, 02/11

Sunday, November 1st

Thursday, October 29th